Can I Take Alpha-Lipoic Acid with Lisinopril?

The direct answer

Alpha-lipoic acid and lisinopril do not have a documented pharmacokinetic interaction: neither drug is known to change how the body absorbs, metabolizes, or clears the other, and there is no CYP450 or protein-binding conflict described in the pharmacology literature reviewed for this page. The interaction that matters is pharmacodynamic. ACE inhibitors like lisinopril have a mild, well-described insulin-sensitizing effect, and ALA has shown its own glucose-lowering and modest blood-pressure-lowering effects in clinical trials using doses of roughly 300 to 1,800 mg per day [7], with some trials also reporting modest blood-pressure-lowering effects. In a person taking lisinopril for hypertension with no other glucose-lowering medication, this overlap is generally not a clinical concern. In a person also taking insulin, a sulfonylurea, or another antihyperglycemic drug, the combined effect is plausible enough that fasting glucose monitoring is a reasonable precaution. No published trial has tested the lisinopril-plus-ALA combination directly, so this guidance is extrapolated from each agent's separate evidence base, not from a head-to-head interaction study.

What each drug is, so it is not confused with something else

Lisinopril is a generic ACE (angiotensin-converting enzyme) inhibitor, sold under brand names including Zestril and Prinivil, taken orally once daily. It is FDA-approved for hypertension, heart failure, and to improve survival after acute myocardial infarction. ACE inhibitors as a drug class are recommended in clinical guidelines to slow progression of diabetic kidney disease, though this is a class-level guideline recommendation rather than a claim specific to lisinopril's own label [1].

Alpha-lipoic acid (ALA), also written as thioctic acid, is a sulfur-containing compound that acts as a cofactor for mitochondrial enzymes (pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase) and has both water- and fat-soluble antioxidant properties [3]. It occurs naturally in small amounts and is sold in the US as an over-the-counter dietary supplement, either as racemic (R/S) ALA or the R-enantiomer alone. It is not an FDA-approved drug for any indication, and unlike lisinopril it is not reviewed by the FDA for safety, efficacy, or interaction potential before it reaches the market.

Why lisinopril alone nudges blood sugar

ACE inhibitors have been associated with a modest reduction in new-onset type 2 diabetes compared with some other blood pressure medications, an effect generally attributed to improved skeletal-muscle blood flow and bradykinin-mediated glucose uptake. A meta-analysis of ACE inhibitor and ARB trials reported this reduction in incident diabetes [2]; the exact relative-risk figure varies across summaries of this literature, so a specific percentage is not repeated here without direct verification against the original paper. The practical point for this page is narrower and better supported: lisinopril's glucose effect in isolation is mild, and it becomes more relevant only when combined with another agent that also lowers glucose.

Why alpha-lipoic acid also affects glucose

ALA activates AMP-activated protein kinase (AMPK) in skeletal muscle, which promotes GLUT4 translocation and glucose uptake through a pathway that does not require insulin. In the SYDNEY 2 trial, oral ALA at 600 mg/day for five weeks improved neuropathic symptoms in people with diabetic peripheral neuropathy without causing severe hypoglycemia as a standalone treatment [4]. A small placebo-controlled trial in people with type 2 diabetes reported improved insulin-stimulated glucose disposal over several weeks of treatment; because this was a small trial, its magnitude should not be assumed to transfer directly to typical over-the-counter ALA use. A systematic review and meta-analysis of oral ALA trials (300 to 1,800 mg/day) in people with metabolic disease reported reductions in fasting glucose and HbA1c across the pooled studies [7]. The exact pooled effect sizes vary by which trials are included and how heterogeneity is handled; a reader who needs the precise numbers for clinical decision-making should pull the original meta-analysis rather than rely on a rounded figure repeated secondhand.

Is the additive hypoglycemia risk established, or just plausible?

This is the honest boundary of the evidence. It is established that both lisinopril and ALA can independently lower blood glucose. It is pharmacologically plausible that combining them adds to that effect, particularly on top of insulin, a sulfonylurea, or an SGLT2 inhibitor. It is not established, in the sense of a dedicated interaction trial, how large that combined effect is in practice, because no published study has tested lisinopril and ALA together. The American Diabetes Association's Standards of Care recommends glucose self-monitoring or continuous glucose monitoring for anyone on glucose-lowering therapy who has hypoglycemia risk [8]; adding ALA to an existing lisinopril-plus-diabetes-medication regimen falls under that same general monitoring logic, even though ALA itself is a supplement rather than a prescription drug.

Evidence-status interaction assessment: lisinopril + alpha-lipoic acid

Blood pressure: two effects pointing the same direction

Some ALA supplementation trials have reported average reductions in both systolic and diastolic blood pressure compared with placebo. For someone whose blood pressure is well controlled on lisinopril with room above their target, an additional small reduction from ALA is unlikely to cause symptoms. For someone already near the lower end of their target range, the added drop could plausibly cause lightheadedness or orthostatic symptoms. Checking sitting and standing blood pressure a few weeks after starting ALA is a reasonable way to catch this early; if symptoms appear, the supplement is generally the easier variable to adjust before changing a prescribed antihypertensive.

Thyroid hormone conversion: an ALA-specific issue, not a lisinopril one

A small study found that high-dose ALA reduced free T3 in healthy volunteers, consistent with inhibition of the enzyme that converts T4 to T3 [6]. Lisinopril itself has no known effect on thyroid hormone levels. This matters for this combination only because a person taking both drugs might also be on thyroid medication or have undiagnosed thyroid disease; in that situation, the ALA effect (not an ALA-lisinopril interaction) is the relevant variable. Anyone on levothyroxine who adds ALA should ask their prescriber about spacing the two and whether a follow-up thyroid panel makes sense, since the deiodinase effect described in this study was not tested against a background of thyroid replacement therapy.

Kidney function and potassium

Lisinopril is often prescribed in diabetic kidney disease because ACE inhibition reduces intraglomerular pressure and proteinuria. An animal study using diabetic rats reported reduced markers of renal oxidative stress with ALA administration [10]; this is preclinical evidence only, and it has not been confirmed in human trials, so it should not be read as evidence that ALA protects the kidneys in people. There is no evidence that ALA worsens renal function or blunts lisinopril's renoprotective effect. On potassium specifically: lisinopril raises serum potassium through reduced aldosterone secretion, and ALA has no known direct effect on potassium homeostasis. People who already have their potassium monitored because of lisinopril or reduced kidney function should continue that existing schedule; adding ALA does not, on current evidence, change what needs to be watched [1].

Should you separate the doses?

No published interaction study has established a required separation window between lisinopril and ALA, because no such interaction trial exists. The common practical suggestion, spacing ALA at least a couple of hours from other pills and taking it away from food, is based on general absorption principles for ALA rather than on a lisinopril-specific finding. If a levothyroxine dose is also part of the regimen, spacing ALA further from that specific medication is the more evidence-relevant precaution, given the deiodinase finding above [6].

What dose of ALA is reasonable, and who should decide it

Clinical trials of ALA for diabetic neuropathy and metabolic outcomes have generally used doses between 300 and 1,800 mg per day, with 600 mg/day used over four years in the NATHAN 1 trial without new safety signals reported in that trial population [11]. This range describes what has been studied, not a personal recommendation. The right starting dose, whether to titrate, and how high to go depend on a person's diabetes medications, kidney function, thyroid status, and blood pressure control, which is individualized information a prescriber or pharmacist is better positioned to weigh than a general reference page.

Who should be cautious or hold off

• Recurrent hypoglycemia (multiple low-glucose episodes in the recent past) is a reason to stabilize glucose control before adding a second glucose-lowering agent, even an over-the-counter one.
• Poorly controlled hypothyroidism is a reason to optimize thyroid replacement before introducing a supplement that may further reduce T4-to-T3 conversion.
• Pregnancy and breastfeeding are reasons to avoid ALA, since human safety data in these populations are limited.
• Insulin, sulfonylureas, or SGLT2 inhibitors taken alongside lisinopril raise the plausibility of additive hypoglycemia enough that glucose monitoring should move from optional to expected if ALA is added.

When this warrants urgent care, not just a follow-up call

Confusion, slurred speech, seizure, or loss of consciousness that could reflect severe hypoglycemia is an emergency; call 911 or go to an emergency department rather than waiting for a scheduled appointment. Fainting, chest pain, or a systolic blood pressure that has dropped sharply with dizziness also warrants urgent evaluation rather than a wait-and-see approach. Repeated fasting glucose readings under 70 mg/dL that are not emergencies, new fatigue or cold intolerance, or a systolic pressure that has settled persistently below the low-90s range are reasons to call the prescriber promptly, but are not automatically 911-level events.

Formulation notes

The R-enantiomer of ALA (R-ALA) is generally reported to be absorbed more efficiently than racemic (R/S) ALA in pharmacokinetic studies [14]; if using R-ALA, a lower milligram dose than racemic ALA trials used may achieve a comparable effect, though this has not been tested specifically against lisinopril. Because ALA is regulated as a supplement rather than a drug, product quality and labeling accuracy vary by manufacturer; a third-party verification mark (such as USP or NSF certification) reduces, but does not eliminate, the risk of contamination or mislabeled dose.

If you are already taking both without problems

Tolerating lisinopril and ALA together without symptoms or glucose excursions is a reasonable sign the combination is working for that individual. It does not remove the value of periodic monitoring, particularly after any dose change to either agent, but it is not, on its own, a reason to stop either medication.